Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesParadigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.245 AUD 0.00(0%)
Last update at 2026-11-04T23:00:00Z
Market Cap
153.48M

Momentum Score

…

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.24
Low
0.24
High
52 Week Price Range
0.14
Low
0.40
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Paradigm Biopharmaceuticals Ltd is an Australian clinical-stage company developing therapies for musculoskeletal disorders, focusing on advancing a repurposed therapeutic candidate for osteoarthritis. Long-term growth drivers include clinical trial progress, regulatory approvals and commercialization execution, and rising demand for non-surgical osteoarthritis treatments, which may benefit investors if late-stage data and approvals progress.
Primary risks include clinical and regulatory failure, ongoing funding needs and commercial execution risk typical of small biotechnology companies.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.24
Dividend Yield
-
Revenue TTM
0.01M
Revenue Per Share
-
Gross Profit TTM
-0.01M
Debt / Equity
2.16
ROE
-456.96%
Net Debt
-7.86M
ROCE
-1538.54%
Diluted EPS TTM
-0.15

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -63.95M -25.30M -58.65M -51.91M -39.25M
Net income -56.33M -18.77M -58.65M -51.91M -39.28M
Selling general administrative 7.26M 5.58M 6.22M 6.56M 7.93M
Selling and marketing expenses - - 0.55M - -
Gross profit -0.08M -0.02M 0.06M 0.03M -0.06M
Reconciled depreciation 0.15M - 0.15M - 0.06M
Ebit -61.11M -25.30M -64.69M -60.04M -39.22M
Ebitda -60.96M -25.25M -64.54M -51.89M -39.16M
Depreciation and amortization 0.15M 0.05M 0.15M - 0.06M
Operating income -61.11M -22.89M -65.19M -51.89M -39.22M
Other operating expenses 61.19M 22.94M 65.11M 60.09M 48.07M
Interest expense 2.46M 0.01M 0.01M 0.02M 0.03M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.42M 0.00M 0.41M 0.41M 0.05M
Net interest income -2.04M - 0.39M 1.39M 0.02M
Income tax expense -7.62M -6.53M -5.97M - 0.03M
Total revenue 0.08M 0.05M 0.07M 0.05M 0.08M
Total operating expenses 61.03M 22.87M 65.10M 60.07M 47.93M
Cost of revenue 0.16M 0.07M 0.01M 0.02M 0.14M
Total other income expense net -2.84M -2.42M 6.54M 6.74M -0.03M
Net income from continuing ops -56.33M - -58.65M -51.91M -39.25M
Net income applicable to common shares - -18.77M -58.65M -51.91M -39.25M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 30.55M 24.57M 27.39M 67.07M 50.69M
Intangible assets 0.91M 0.41M - 2.95M 2.95M
Other current assets 0.64M 0.94M 1.30M - 0.78M
Total liab 27.08M 3.39M 3.58M 13.39M 8.38M
Total stockholder equity 3.47M 21.18M 23.81M 53.68M 42.31M
Other current liab 2.28M 0.49M 0.42M 0.78M 0.59M
Common stock 289.96M 253.23M 238.11M 209.83M 147.19M
Capital stock 289.96M - - 209.83M 147.19M
Retained earnings -288.52M -235.95M -220.73M -163.51M -114.02M
Other liab - - - 0.11M 0.08M
Other assets - - 0.00M - 0.00M
Cash 15.37M 16.82M 17.82M 56.33M 39.67M
Total current liabilities 26.58M 3.23M 3.36M 13.04M 7.83M
Net debt -7.86M -16.81M -17.58M -55.99M -39.06M
Short term debt 7.15M 0.01M 0.12M 0.10M 0.15M
Short long term debt 7.00M - - - -
Short long term debt total 7.51M 0.01M 0.24M 0.34M 0.62M
Other stockholder equity - - - -0.43M 9.13M
Property plant equipment - - - 0.34M 0.57M
Total current assets 29.15M 24.13M 24.25M 63.79M 47.17M
Net tangible assets - - - 50.73M 39.37M
Short term investments 0.07M - 0.05M 0.05M 0.05M
Net receivables 13.06M 6.37M 5.08M 6.81M 6.72M
Accounts payable 17.15M 2.73M 2.82M 12.16M 7.09M
Accumulated other comprehensive income 2.03M 3.90M 6.42M 7.36M 9.13M
Non currrent assets other - - 2.95M - -
Non current assets total 1.40M 0.44M 3.14M 3.28M 3.52M
Capital lease obligations 0.51M - - 0.34M 0.62M
Long term debt total - - - 0.14M 0.37M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments -0.07M - - - -
Change to liabilities - - - 5.07M 2.10M
Total cashflows from investing activities -0.55M 0.05M - 0.00M 0.00M
Net borrowings 23.17M - - -0.10M -0.14M
Total cash from financing activities 43.69M 14.99M 28.18M 62.53M 0.07M
Change to operating activities - - - -0.10M 0.54M
Net income -56.33M -18.77M -58.65M -51.91M -39.28M
Change in cash -1.45M -1.00M -38.51M 16.66M -31.36M
Begin period cash flow 16.82M 17.82M 56.33M 39.67M 71.03M
End period cash flow 15.37M 16.82M 17.82M 56.33M 39.67M
Total cash from operating activities -43.69M -15.99M -65.94M -45.19M -39.22M
Issuance of capital stock 21.57M - 30.12M 65.99M -
Depreciation 0.15M 0.05M 0.15M 0.15M 0.06M
Other cashflows from investing activities - 0.05M -65.94M 0.00M 0.00M
Change to account receivables -6.69M -0.31M 1.29M 0.36M 1.79M
Sale purchase of stock -1.00M 16.00M -1.84M -3.76M 0.00M
Other cashflows from financing activities -0.13M -0.13M -0.10M 0.31M 0.07M
Change to netincome - - - 1.24M 2.41M
Capital expenditures 0.49M 0.00M 65.94M 0.00M 0.00M
Change in working capital 8.15M 0.10M -8.68M 0.95M 0.05M
Stock based compensation - - 1.20M - -
Other non cash items 4.34M 2.63M 1.25M - 39.22M
Free cash flow -43.69M -15.99M -65.94M -45.19M -39.22M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
PAR
Paradigm Biopharmaceuticals Ltd		 -
-%		 0.24 - 8.12 1131.11 44.22 1815.86 -6.78
CSL
CSL Ltd		 -0.36
0.18%		 202.04 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.41
2.91%		 13.67 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -
-%		 23.24 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.14
6.45%		 2.03 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

500 Collins Street, Melbourne, VIC, Australia, 3000

61 3 9629 5566

https://www.paradigmbiopharma.com

Name Title Year Born
Mr. Paul John Rennie BSc, Grad Dip, MBM, MSTC Founder, MD & Exec. Chairman 1959
Dr. Donna L. Skerrett M.D., MS Chief Medical Officer and Exec. Director 1957
Mr. Justin Cahill Chief Financial Officer NA
Dr. Ravi Krishnan Chief Scientific Officer NA
Mr. Simon White Director of Investor Relations NA
Dr. Michael Imperiale Global Head of Drug Safety & MPS NA
Ms. Beverley Huttmann Commercial Head NA
Ms. Michelle Coffey Global Head of Regulatory Affairs NA
Dr. Mukesh Ahuja Global Clinical Head of OA NA
Mr. Marco Polizzi Exec. Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…